BACKGROUND: The detection of occult carcinoma cells in patients with breast cancer has been shown to predict disease recurrence and metastasis. MATERIALS AND METHODS: To improve on molecular detection of breast carcinoma cells in blood, we have developed a sensitive and quantitative assay using real-time quantitative RT-PCR identifying transcripts of the cytokeratin-19 (CK19) gene. RESULTS: This real-time quantitative RT-PCR is sensitive, accurate and has a high reproducibility within a wide dynamic range, which permits simultaneous quantitative analysis of samples with varying input concentrations. Furthermore, the procedure offers several technical advantages over classic quantitative PCR methods (competitive RT-PCR, Northern blotting) such as decreased likelihood of contamination due to absence of post-PCR manipulations, high sample throughput because of absence of post-PCR processing time (no agarose gel electrophoresis). In this pilot study, we detected significantly elevated CK19 transcript levels in < 10% of the volunteers, in +/- 30% of stage I-IIIa patients preoperatively and in > 70% of the and stage IV breast cancer patients. CONCLUSIONS: Analyses using this real time quantitative RT-PCR for CK19 mRNA may prove to have clinical implications in the assessment of circulating tumour cells in peripheral blood, micrometastases in bone marrow or lymph nodes in breast cancer patients. Application of this technique in a clinical population may improve diagnosis and monitoring of metastatic breast cancer and its validation is currently ongoing.
BACKGROUND: The detection of occult carcinoma cells in patients with breast cancer has been shown to predict disease recurrence and metastasis. MATERIALS AND METHODS: To improve on molecular detection of breast carcinoma cells in blood, we have developed a sensitive and quantitative assay using real-time quantitative RT-PCR identifying transcripts of the cytokeratin-19 (CK19) gene. RESULTS: This real-time quantitative RT-PCR is sensitive, accurate and has a high reproducibility within a wide dynamic range, which permits simultaneous quantitative analysis of samples with varying input concentrations. Furthermore, the procedure offers several technical advantages over classic quantitative PCR methods (competitive RT-PCR, Northern blotting) such as decreased likelihood of contamination due to absence of post-PCR manipulations, high sample throughput because of absence of post-PCR processing time (no agarose gel electrophoresis). In this pilot study, we detected significantly elevated CK19 transcript levels in < 10% of the volunteers, in +/- 30% of stage I-IIIa patients preoperatively and in > 70% of the and stage IV breast cancerpatients. CONCLUSIONS: Analyses using this real time quantitative RT-PCR for CK19 mRNA may prove to have clinical implications in the assessment of circulating tumour cells in peripheral blood, micrometastases in bone marrow or lymph nodes in breast cancerpatients. Application of this technique in a clinical population may improve diagnosis and monitoring of metastatic breast cancer and its validation is currently ongoing.
Authors: Liqiang Xi; Michael C Coello; Virginia R Litle; Siva Raja; William E Gooding; Samuel A Yousem; Talal El-Hefnawy; Rodney J Landreneau; James D Luketich; Tony E Godfrey Journal: Clin Cancer Res Date: 2006-04-15 Impact factor: 12.531
Authors: Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini Journal: J Mol Diagn Date: 2006-02 Impact factor: 5.568
Authors: Sa Deepak; Kr Kottapalli; R Rakwal; G Oros; Ks Rangappa; H Iwahashi; Y Masuo; Gk Agrawal Journal: Curr Genomics Date: 2007-06 Impact factor: 2.236
Authors: Wildeman Zapata; Benigno Rodriguez; Jan Weber; Hernando Estrada; Miguel E Quiñones-Mateu; Peter A Zimermman; Michael M Lederman; Maria T Rugeles Journal: Curr HIV Res Date: 2008-11 Impact factor: 1.581
Authors: I Van der Auwera; D Peeters; I H Benoy; H J Elst; S J Van Laere; A Prové; H Maes; P Huget; P van Dam; P B Vermeulen; L Y Dirix Journal: Br J Cancer Date: 2009-12-01 Impact factor: 7.640